Table 6.
Medication Prescription Rates Before and After Publication of COURAGE in the 90 Days After PCI
| Medication | Total | No. (%), (95% CI) of patients | P‐Value* | |
|---|---|---|---|---|
| Pre‐COURAGE | Post‐COURAGE | |||
| Post‐PCI | ||||
| Optimal medical therapy | 11 149 (47.1%) | 47.3 (46.4 to 48.2) | 46.9 (46.0 to 47.8) | 0.520 |
| Suboptimal medical therapy | 11 591 (48.9%) | 49.1 (48.2 to 50.0) | 48.8 (47.9 to 49.7) | 0.567 |
| None | 940 (4.0%) | 3.6 (3.3 to 3.9) | 4.4 (4.0 to 4.7) | 0.002 |
| Individual medications | ||||
| Long‐acting nitrate | 3426 (14.5%) | 15.9 (15.2 to 16.5) | 13.0 (12.4 to 13.7) | <0.001 |
| β‐Blocker | 16 729 (70.6%) | 71.3 (70.5 to 72.1) | 70.0 (69.1 to 70.8) | 0.023 |
| Calcium channel blocker | 7320 (30.9%) | 31.4 (30.5 to 32.2) | 30.4 (29.6 to 31.3) | 0.125 |
| Statin | 20 028 (84.6%) | 84.1 (83.4 to 84.8) | 85.1 (84.4 to 85.7) | 0.038 |
| ACE‐I/ARB | 17 638 (74.5%) | 75.9 (75.1 to 76.6) | 73.1 (72.3 to 73.9) | <0.001 |
| Clopidogrel | 20 629 (87.1%) | 86.7 (86.1 to 87.3) | 87.5 (86.9 to 88.1) | 0.053 |
| Symptom‐oriented medical therapy | 57.9 (57.3, 58.5) | 58.2 (57.3 to 59.1) | 57.6 (56.7 to 58.5) | 0.316 |
Optimal medical therapy is defined as prescription for β‐blocker, statin, and either ACE inhibitor or ARB along with a thienopyridine in the 90 days following PCI. Suboptimal therapy is defined as prescription of at least 1 of the above individual medications. Symptom‐oriented medical therapy is defined as the prescription of any 2 medications from the following: β‐blocker, long‐acting nitrate, calcium channel blocker or either ACE inhibitor or ARB, along with a thienopyridine and statin in the 90 days following PCI. ACE‐I indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; COURAGE, Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation; PCI, percutaneous coronary intervention.
McNemar test.